Compendium of Cancer Genome Aberrations

HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

[unchecked revision][unchecked revision]
← Older editNewer edit →
VisualWikitext
No edit summary
No edit summary
Line 731: Line 731:
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma
|Disease
|
|
|
|
|
|
|Holli Drendel (HD)
|
|
|
|
|
|
|-
|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy
|Disease
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|
|
|
|
|
|
|
|
|HD
|
|
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with hypodiploidy
|Disease
|Ashwini Yenamandra PhD FACMG  Lisa Smith PhD FACMG  Yassmine Akkari PhD FACMG
|
|
|
|
|
|
|
|
|HD
|
|
|
|
|
|
|-
|B-lymphoblastic leukaemia/lymphoma with iAMP21
|Disease
|Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte
|
|
|
|
|
|HD
|
|
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion
|Disease
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|
|
|
|
|
|
|
|
|HD
|
|
|
|
|
|
|-
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features
|Disease
|Mark G. Evans, MD, University of California, Irvine  Fabiola Quintero-Rivera, MD, University of California, Irvine
|
|
|
|
|
|HD
|
|
|
|
|
|
|-
|-
|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement
|Disease
|Yassmine Akkari  Nicolas Millan
|
|
|
|
|
|
|
|
|HD
|
|
|
|-
|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion
|Disease
|Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG  Cancer Category/Type    B-Lymphoblastic Leukemia/Lymphoma
|
|
|
|
|
|
|
|
|HD
|
|
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features
|Disease
|
|
|
|
|
|
|
|
|
|HD
|
|
|
|-
|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion
|Disease
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|
|
|
|
|
|
|
|
|HD
|
|
|
|
|
|
|-
|-
|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion
|Disease
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|
|
|
|
|
|
|HD
|
|
|
|
|
|
|-
|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion
|Disease
|
|
|
|
|
|
|
|
|HD
|
|
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations
|Disease
|
|
|
|
Line 808: Line 882:
|
|
|
|
|HD
|
|
|
|
|
|
|-
|B-lymphoblastic leukaemia/lymphoma, NOS
|Disease
|
|
|
|
|
|
|
|
|HD
|
|
|
|-
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
|
| ||
|-
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG||
| ||
|-
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG||
| ||
|-
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG||
| ||
|-
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG||
| ||
|-
|-
|Splenic B-cell lymphoma/leukaemia with prominent nucleoli
|Disease
|*Snehal Patel, MD, PhD
|
|
|
|
|
|
|
|
|SG
|
|
|
|
|
|
|-
|Lymphoplasmacytic lymphoma
|Disease
|Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and *Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
|
|
|
|
|
|SG
|
|
|
|
|
|
|-
|-
|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
|Disease
|
|
|
|
|
|
|
|SG
|
|
|
|
|
|
|-
|Primary cutaneous marginal zone lymphoma
|Disease
|
|
|
|
|
|
|
|
|SG
|
|
|
|
|
|
|-
|-
|Nodal marginal zone lymphoma
|Disease
|Andrew Ly, DO and Shivani Golem, PhD, FACMG
|
|
|
|
|
|SG
|
|
|
|
|
|
|-
|Paediatric nodal marginal zone lymphoma
|Disease
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD
|
|
|
|
|
|
|
|
|SG
|
|
|
|
|
|
|-
|-
|In situ follicular B-cell neoplasm
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|
|
|
|
|
|
|
|
|SG
|
|
|
|
|
|
|-
|Follicular lymphoma
|Disease
|Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital  Rachel D. Burnside, PhD, MBA, FACMG, University of Florida
|
|
|
|
|
|SG
|
|
|
|
|
|
|-
|-
|Paediatric-type follicular lymphoma
|Disease
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG
|
|
|
|
|
|SG
|
|
|
|
|
|-
|Duodenal-type follicular lymphoma
|Disease
|
|
|
|
Line 871: Line 1,030:
|
|
|
|
|SG
|
|
|
|
|
|
|-
|-
|Primary cutaneous follicle centre lymphoma
|Disease
|Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG
|
|
|
|
|
|
|SG
|
|
|
|
|
|-
|In situ mantle cell neoplasm
|Disease
|Rina Kansal, MD; Versiti Blood Center of Wisconsin
|
|
|
|
|
|
|
|
|SG
|
|
|
|
|
|
|-
|-
|Mantle cell lymphoma
|Disease
|* Mahsa Khanlari, MD * Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
|
|
|
|
|
|
|
|
|SG
|
|
|
|-
|Leukaemic non-nodal mantle cell lymphoma
|Disease
|<br />
|
|
|
|
|
|
|
|
|SG
|
|
|
|
|
|
|-
|-
| || || || || || || || ||
|Transformations of indolent B-cell lymphomas
| ||
|Disease
|
|
|
|
|
|SG
|
|
|
|-
|-
| || || || || || || || ||
|
| ||
|
|-
|
| || || || || || || || ||
|
| ||
|
|-
|
| || || || || || || || ||
|
| ||
|
|-
|
| || || || || || || || ||
|
| ||
|
|-
|-
|
|
Line 962: Line 1,155:
|
|
|-
|-
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
|
|
|
|
----<br />
|
|
----<br />
|
|
|
|
|
Line 976: Line 1,167:
|
|
|-
|-
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)
|
|
|
|
----<br />
|
|
----<br />
|
|
|
|
|
Line 990: Line 1,179:
|
|
|-
|-
|CHAPTER 7 (GENETIC TUMOUR SYNDROMES)
|
|
|
|
----<br />
|
|
----<br />
|
|
|
|
|
Line 1,091: Line 1,278:
| ||
| ||
|-
|-
|B-lymphoblastic leukaemia/lymphoma
|Disease
|
|
|
|
Line 1,098: Line 1,283:
|
|
|
|
|Holli Drendel (HD)
|
|
|
|
|
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy||Disease||Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG|| || || || ||HD||
| || || || || || || || ||
| ||
| ||
|-
|-
|B-lymphoblastic leukaemia/lymphoma with hypodiploidy||Disease||Ashwini Yenamandra PhD FACMG  Lisa Smith PhD FACMG  Yassmine Akkari PhD FACMG|| || || || ||HD||
| || || || || || || || ||
| ||
| ||
|-
|-
|B-lymphoblastic leukaemia/lymphoma with iAMP21||Disease||Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte|| || || || ||HD
| || || || || || || ||
|
|
| ||
| ||
|-
|-
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion||Disease||Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG|| || || || ||HD
| || || || || || || ||
|
|
| ||
| ||
|-
|-
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features||Disease||Mark G. Evans, MD, University of California, Irvine  Fabiola Quintero-Rivera, MD, University of California, Irvine|| || || || ||HD
| || || || || || || ||
|
|
| ||
| ||
|-
|-
|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement||Disease||Yassmine Akkari  Nicolas Millan|| || || || ||HD
| || || || || || || ||
|
|
| ||
| ||
|-
|-
|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion||Disease||Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG  Cancer Category/Type    B-Lymphoblastic Leukemia/Lymphoma|| || || || ||HD
| || || || || || || ||
|
|
| ||
| ||
|-
|-
|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features||Disease|| || || || || ||HD
| || || || || || || ||
|
|
| ||
| ||
|-
|-
|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion||Disease||Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO|| || || || ||HD
| || || || || || || ||
|
|
| ||
| ||
|-
|-
|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion||Disease||Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO|| || || || ||HD
| || || || || || || ||
|
|
| ||
| ||
|-
|-
|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion||Disease|| || || || || ||HD
| || || || || || || ||
|
|
| ||
| ||
|-
|-
|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations||Disease|| || || || || ||HD
| || || || || || || ||
|
|
| ||
| ||
|-
|-
|B-lymphoblastic leukaemia/lymphoma, NOS||Disease|| || || || || ||HD
| || || || || || || ||
|
|
| ||
| ||
Line 1,243: Line 1,430:
| ||
| ||
|-
|-
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||SP||
| || || || || || || || ||
| ||
| ||
|-
|-
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SP||
| || || || || || || || ||
| ||
| ||
|-
|-
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SP||
| || || || || || || || ||
| ||
| ||
|-
|-
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SP||
| || || || || || || || ||
| ||
| ||
|-
|-
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SP||
| || || || || || || || ||
| ||
| ||
|-
|-
|Splenic B-cell lymphoma/leukaemia with prominent nucleoli||Disease||*Snehal Patel, MD, PhD|| || || || ||SP||
| || || || || || || || ||
| ||
| ||
|-
|-
|Lymphoplasmacytic lymphoma||Disease||Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and *Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)|| || || || ||SP||
| || || || || || || || ||
| ||
| ||
|-
|-
|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue||Disease|| || || || || ||SP||
| || || || || || || || ||
| ||
| ||
|-
|-
|Primary cutaneous marginal zone lymphoma||Disease|| || || || || ||SP||
| || || || || || || || ||
| ||
| ||
|-
|-
|Nodal marginal zone lymphoma||Disease||Andrew Ly, DO and Shivani Golem, PhD, FACMG|| || || || ||SP||
| || || || || || || || ||
| ||
| ||
|-
|-
|Paediatric nodal marginal zone lymphoma||Disease||* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD|| || || || ||SP||
| || || || || || || || ||
| ||
| ||
|-
|-
|In situ follicular B-cell neoplasm||Disease||Rachel D. Burnside, PhD, MBA, FACMGG|| || || || ||SP||
| || || || || || || || ||
| ||
| ||
|-
|-
|Follicular lymphoma||Disease||Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital  Rachel D. Burnside, PhD, MBA, FACMG, University of Florida|| || || || ||SP||
| || || || || || || || ||
| ||
| ||
|-
|-
|Paediatric-type follicular lymphoma||Disease||*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG|| || || || ||SP||
| || || || || || || || ||
| ||
| ||
|-
|-
|Duodenal-type follicular lymphoma||Disease|| || || || || ||SP||
| || || || || || || || ||
| ||
| ||
|-
|-
|Primary cutaneous follicle centre lymphoma||Disease||Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG|| || || || ||SP||
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)|| ||
----<br />||
----<br />|| || || || ||
| ||
| ||
|-
|-
|In situ mantle cell neoplasm||Disease||Rina Kansal, MD; Versiti Blood Center of Wisconsin|| || || || ||SP||
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)|| ||
----<br />||
----<br />|| || || || ||
| ||
| ||
|-
|-
|Mantle cell lymphoma||Disease||* Mahsa Khanlari, MD * Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SP||
|CHAPTER 7 (GENETIC TUMOUR SYNDROMES)|| ||
----<br />||
----<br />|| || || || ||
| ||
| ||
|-
|-
|Leukaemic non-nodal mantle cell lymphoma||Disease||<br />|| || || || ||SP||
| || || || || || || || ||
| ||
| ||
|-
|-
|Transformations of indolent B-cell lymphomas||Disease|| || || || || ||SP||
| || || || || || || || ||
| ||
| ||
|-
|
|
|
|
|
|
|
|
|
|
|
|-
|-
|Cold agglutinin disease||Disease|| || || || || ||SP||
|Cold agglutinin disease||Disease|| || || || || ||SP||
Retrieved from "https://test.ccga.io/index.php/HAEM5:Volunteer_Assignments_and_Opportunities"